Dan Klein, president and CEO of the Patient Access Network (PAN) Foundation, discusses the need for more patient assistance foundations to help patients pay for treatment.
Dan Klein, president and CEO of the Patient Access Network (PAN) Foundation, discusses the need for more patient assistance foundations to help patients pay for treatment.
Transcript
What is the overall impact that patient assistance foundations, like PAN, have on helping patients access treatments?
Well we serve anywhere between 150,000 to 250,000 patients a year depending on how much funding we have available. In the past couple of years, we’ve served about 150,000 patients a year and we’re the largest of the major charitable foundations so we’re serving about 40% to 50% of the patients who get charitable assistance. My guess is, there are probably 1 million or so patients a year getting charitable support from the 7 to 9 largest foundations.
The problem is that we can’t serve everybody who comes to us for a grant. Now we do refer them to other charities. But my guess is that there are 2 or 3 times the number of people who need help who can’t actually get it.
How do you envision the role of PAN will change and expand as more novel therapies that are potentially curative, but expensive, come to market?
The worry we have is some of these very innovative new therapies, like CAR T therapies, other gene therapies, are going to be so expensive that health plans may struggle to find ways to pay for them and patient out-of-pocket costs could be essentially unaffordable for patients. So, we think they’re gonna be probably new ways to finance these kinds of treatments that will spread the cost over a longer period than the traditional benefit does. We are not sure what those will be but we know that half a million dollar and million dollar products come to the market, there are going to have to be new ways to finance those.
NGS-Based Test Accurately Detects Post–Allo-HSCT Relapse in AML, MDS
February 21st 2025The next-generation sequencing (NGS)–based AlloHeme test accurately predicted relapse following allogeneic hematopoietic stem cell transplantation (allo-HSCT) in acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS).
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions
June 28th 2022On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
Listen
“Expanding Access Isn’t Just About Fairness—It’s About Building Better Treatments for Everyone”
February 16th 2025Regina Barragan-Carrillo, MD, a postdoctoral fellow at City of Hope Comprehensive Cancer Center, discussed findings that show 76% of renal cell carcinoma trials take place in wealthy countries, amid news that clinical trial access for the world's poor may become even more challenging.
Read More
Amid Debate Over Diversity, RCC Trials Still Struggle to Reflect Patient Populations
February 16th 2025Abstracts presented at the American Society of Clinical Oncology Genitourinary Cancers Symposium reflect the ongoing challenge with enrolling diverse patient populations in trials, despite stated goals.
Read More